TIDMGEN
Company Announcement
COPENHAGEN, Denmark; September 27, 2022 --
https://www.globenewswire.com/Tracker?data=dp6eJzYcJt3U7DpOlpEcn6h_sjQQimQZYuWlMIXJQnlxkSh8K1D3TPNOTxtby-Yiw65Wrn7jvcZtSOrglfiwhA==
Genmab A/S (Nasdaq: GMAB) will increase its share capital by 18,406
shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the
existing shareholders of the company or others. The shares are
subscribed in cash at the following price per share of nominally
DKK 1:
133 shares at DKK 815.50,
3,874 shares at DKK 939.50,
367 shares at DKK 962.00,
8,949 shares at DKK 1,025.00,
878 shares at DKK 1,032.00,
50 shares at DKK 1,050.00,
2,990 shares at DKK 1,145.00,
200 shares at DKK 1,161.00,
562 shares at DKK 1,210.00,
158 shares at DKK 1,233.00,
33 shares at DKK 1,402.00,
72 shares at DKK 1,424.00, and
140 shares at DKK 1,432.00.
Proceeds to the company are approximately DKK 19.1 million. The
increase corresponds to approximately 0.03% of the company's share
capital.
The new shares are ordinary shares without any special rights
and are freely transferable negotiable instruments. The new shares
give rights to dividends and other rights in relation to the
company as of subscription. The new shares will be listed on Nasdaq
Copenhagen after registration with the Danish Business Authority.
The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No.
2014 of November 1, 2021, it is hereby announced, that the total
nominal value of Genmab A/S' share capital after the capital
increase is DKK 65,829,282 which is made up of 65,829,282 shares of
a nominal value of DKK 1 each, corresponding to 65,829,282
votes.
About Genmab
Genmab is an international biotechnology company with a core
purpose to improve the lives of people with cancer. For more than
20 years, Genmab's vision to transform cancer treatment has driven
its passionate, innovative and collaborative teams to invent
next-generation antibody technology platforms and leverage
translational research and data sciences, fueling multiple
differentiated cancer treatments that make an impact on people's
lives. To develop and deliver novel therapies to patients, Genmab
has formed 20+ strategic partnerships with biotechnology and
pharmaceutical companies. Genmab's proprietary pipeline includes
bispecific T-cell engagers, next-generation immune checkpoint
modulators, effector function enhanced antibodies and antibody-drug
conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in
Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo,
Japan. For more information, please visit Genmab.com
https://www.globenewswire.com/Tracker?data=dp6eJzYcJt3U7DpOlpEcnx5ar7ejGlP64p333qQqaow_5BlRhXLWwO-YRFQMt_OKYaxwZmcrlwvOxJOV2e_adQ==
and follow us on Twitter.com/Genmab
https://www.globenewswire.com/Tracker?data=9Rg4iC9wVF9NE-EFFDCRr0AlMTcB1BGfph5xzuB4f4W0WDdYrvU_37hPjX2J6iV7hMQp_v2XbUn1R1nR6wW8UbdL-5EPSHMXYdR6i_mW_lk=
.
Contact:
Marisol Peron, Senior Vice President, Communications and
Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
https://www.globenewswire.com/Tracker?data=TM8nUwHeduUJ500oYkowAjLhTfgrc5NdDjYl6jQxenbs-oYK_A2Wt9W87RFr5hzwc0ghoiTulVxtzl_SgoQKgw==
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
https://www.globenewswire.com/Tracker?data=joNhz8XnFx1UXsFarY_2YrWPXaitfLd_NhbVFXbTDAKEVzn4sHfWGhfonBDwXciSSuEezR8PG12C_g9uayLYqA==
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=rfZvflNAiNl0av8sAK8okou5eF6-f8sdXrgsS75y8sRPCz0d07YGj5E2N20SpTWufQa_Qbba73rPjQkXfBfHRQ==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=rfZvflNAiNl0av8sAK8okppYSgZmowmRAb3TwjPENqoGhTbkc8mLSt9rXFbK0P8xL5aIskD6qKRjTt8AHt1iULW_b0T6H-T0-J4luNQiNOM=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor
to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Company Announcement no. 51
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 270922_CA51_Warrant Exercise
https://ml-eu.globenewswire.com/Resource/Download/14f41388-6878-4884-a606-7b51fe91aba0
(END) Dow Jones Newswires
September 27, 2022 12:43 ET (16:43 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Apr 2024 to May 2024
Genuit (LSE:GEN)
Historical Stock Chart
From May 2023 to May 2024